Lenvatinib Plus DEB-TACE and HAIC vs. Lenvatinib Plus DEB-TACE for Large HCC With PVTT

NCT06492395 · tracked via the Priya Life Science China tracker

Sponsor

Second Affiliated Hospital of Guangzhou Medical University

Phase

Phase 3

Started

2024-08-01

Last updated

2025-01-29

Condition(s) studied

Hepatocellular Carcinoma Non-resectable

Investigational drug(s) / intervention(s)

Len+DEB-TACE+HAICLen+DEB-TACE

Len+DEB-TACE+HAIC: For DEB-TACE, superselective catheterization is performed and DEBs loaded with pirarubicin is use for chemoembolization. The embolization end point was blood stasis of the tumor-feeding arteries. In order to reduce the risk of complications, the embolization end point was not achieved in the initial TACE but in the second or third TACE session. After each chemoembolization, the microcatheter is reserved at the main hepatic tumor-feeding artery. The FOLFOX-based regimen is intra-arterially administered. During follow-up, the treatment of DEB-TACE and/or HAIC will be repeated for viable tumors based on the evaluation of the follow-up laboratory and imaging examination. Lenvatinib 12mg (body weight ≥60kg) or 8mg (body weight \<60kg) P.O. qd will be started with 7 days after the first DEB-TACE+HAIC.

Len+DEB-TACE: For DEB-TACE, superselective catheterization is performed and DEBs loaded with pirarubicin is use for chemoembolization. The embolization end point was blood stasis of the tumor-feeding arteries. In order to reduce the risk of complications, the embolization end point was not achieved in the initial TACE but in the second or third TACE session. During follow-up, the treatment of DEB-TACE will be repeated for viable tumors based on the evaluation of the follow-up laboratory and imaging examination. Lenvatinib 12mg (body weight ≥60kg) or 8mg (body weight \<60kg) P.O. qd will be started with 7 days after the first DEB-TACE+HAIC.

Study summary

This study is conducted to evaluate the efficacy and safety of lenvatinib plus transarterial chemoembolization (TACE) with drug-eluting beads (DEB-TACE) and hepatic artery infusion chemotherapy (HAIC) with FOLFOX regemen (Len+DEB-TACE+HAIC) versus lenvatinib plus DEB-TACE (Len+DEB-TACE) for large hepatocellular carcinoma (\> 7cm) with portal vein tumor thrombosis (PVTT).

Eligibility

Sex

ALL

Min age

18 Years

Max age

75 Years

Healthy volunteers

Inclusion Criteria: * a confirmed diagnosis of HCC * the largest intrahepatic lesion \>7 cm * presence of PVTT on imaging * tumor recurrence after curative treatment (hepatectomy or ablation) is eligible for enrollment * Eastern Cooperative Oncology Group performance status ≤1 * Child-Pugh class A/B * adequate hematologic and organ function, with leukocyte count\>3.0×10\^9/L, neutrophil count\>1.5×10\^9/L, platelet count≥75×10\^9/L, hemoglobin 85 g/L, alanine transaminase and aspartate transaminase≤5×upper limit of the normal, creatinine clearance rate≤1.5×upper limit of the normal * life expectancy of at least 3 months Exclusion Criteria: * Diffuse HCC * accompanied with vena cava tumor thrombus * central nervous system involvement * previous treatment with TACE, HAIC, TAE, radiotherapy, or systemic therapy * organ (heart and kidneys) dysfunction, unable to tolerate TACE or HAIC treatment * history of other malignancies * uncontrollable infection * history of HIV * history of organ or cells transplantation * prothrombin time prolongation \>4 s

Primary outcome measure(s)

Time to progression (TTP) — 2 years
The time from date of randomization until the first occurrence of disease progression (according to mRECIST).

Trial sites (1)

Facility	City	Region	Status
The Second Affiliated Hospital of Guangzhou Medical University	Guangzhou	Guangdong	Recruiting

More Second Affiliated Hospital of Guangzhou Medical University trials in China

Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors Recruiting

Triple Hypoglycemic Regimens In Patients With Newly Diagnosed Type 2 Diabetes Mellitus Recruiting

Y-90 SIRT for Unresectable HCC Larger Than 7cm Recruiting

iCAGES-guided Precision Therapy for Cancers in Contrast to Standard Care or IHC-guided Theray Recruiting

Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors Recruiting

Other trials for the same condition

Observational Study for SIR-Spheres Therapy for the Treatment of HCC Patients in China Enrolling by invitation

TACE Combined With Immune Checkpoint Inhibitors for Liver Malignant Tumors Recruiting

Y-90 SIRT for Unresectable HCC Larger Than 7cm Recruiting

Sintilimab Plus Bevacizumab and SIRT for Intermediate-advanced HCC Recruiting

Sintilimab+Bevacizumab+TACE vs. Lenvatinib+TACE for Advanced HCC Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06492395 on ClinicalTrials.gov ↗ ← All trials in China